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Abstract There is currently a wealth of information regard-
ing the mutations that contribute to cancer development.
Most of these mutations alter the expression and activity
of signal transduction proteins. The current goal in cancer
therapy is to use our knowledge of the molecular alterations
in a cancer cell to choose the most appropriate signal trans-
duction inhibitor for an individual patient. The topic of this
review is the mammalian target of rapamycin (mTOR) kinase
signaling pathway, which is aberrantly activated in many
types of human cancer. We will discuss the mTOR pathway
and the potential mechanisms that contribute to its activation
in cancer, together with data relating to the potential for
inhibitors targeting the mTOR-signaling pathway to impact on
breast cancer therapy.
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Abbreviations
AMPK AMP- activated protein kinase
CML chronic myelogenous leukemia
eIF-4E eukaryotic initiation factor 4E
ER estrogen receptor
FGFR fibroblast growth factor receptor
FKBP12 FK506-binding protein-12
FTI farnesyltransferase inhibitor
HIF hypoxia inducible transcription factor
HMEC human mammary epithelial cells
IGF-1R insulin like growth factor-1 receptor
LOH loss of heterozygosity
mTOR mammalian target of rapamycin
PDK1 phosphoinositide dependent protein kinase 1
PH plekstrin homology




PKB protein kinase B
PTEN phosphatase and tensin homologue deleted in
chromosome 10
RTK receptor tyrosine kinase
STI signal transduction inhibitor
S6K1 ribosomal S6 kinase
TKI tyrosine kinase inhibitor
TSC tuberous sclerosis complex
4E-BP1 eukaryotic initiation factor 4E-binding protein 1
Introduction
The current goal in cancer therapy is to define the molecular
alterations underlying the malignant phenotype. With a
better description of these it should be possible to choose
the appropriate signal transduction inhibitor (STI) for an
individual patient. The topic of this review is the mammalian
target of rapamycin (mTOR) kinase signaling pathway,
which is aberrantly activated in many types of human cancer.
TOR was originally identified by genetic means in the bud-
ding yeast Saccharomyces cerevisiae as the target of the
macrolide antibiotic rapamycin [1]. Rapamycin is a potent
suppressor of the immune system [2, 3] and some of its
analogues are currently under intense study as anti-cancer
agents (reviewed in [4, 5]). We will discuss the mTOR
pathway and the potential mechanisms that contribute to its
activation in cancer, together with data relating to the
potential for STIs targeting the mTOR-signaling pathway
to impact on cancer therapy.
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mTOR is a member of the phosphoinositide kinase-related
kinase (PIKK) family consisting of large serine/threonine
kinases including ATM, ATR and DNA-PK, all involved
in stress checkpoint control [6]. mTOR is a central
regulator of cellular responses to multiple stimuli including
amino acid availability [7], energy and oxygen stresses [8, 9]
and growth factor receptor signaling [10]. In cells with
sufficient nutrients, mTOR relays a signal to the translational
machinery leading to an enhanced translation of mRNAs
encoding proteins essential for cell growth and cell cycle
progression (reviewed in [4, 11]). These functions are
specifically mediated by the mTOR–Raptor (also named
mTORC1) complex comprising the regulatory protein GβL
and Raptor; Raptor being suggested to function as an adaptor
to recruit mTOR substrates [12–14].
mTOR has also been identified in a second complex con-
taining the Rictor protein [15, 16]. The mTOR–Rictor complex
controls actin cytoskeleton organization. Moreover, mTOR–
Rictor has been described as a potential kinase for Ser473 in the
hydrophobic regions of the Akt/PKB serine/threonine kinase
[16]. mTOR–Rictor regulation and functions are still poorly
understood and will not be further addressed in this review.
mTOR Effectors
The mTOR–Raptor complex signals directly to important
translational regulators, the translational repressor protein
eukaryotic initiation factor 4E (eIF-4E)-binding protein 1
(4E-BP1) and ribosomal S6 kinase (S6K1). Binding of 4E-
BP1 to eIF-4E is controlled by mTOR dependent phosphor-
ylation of specific serine and threonine residues [17]. Once
4E-BP1 is completely phosphorylated [18], it dissociates from
eIF-4E allowing the formation of a translationally competent
initiation factor complex eIF-4F [17]. eIF-4F activation results
in translation of a subset of capped mRNA containing highly
structured 5′-untranslated regions and encoding proteins
involved in G1- to S-phase progression, such as c-myc [19]
and cyclin D1 [20–22]. The second important mTOR target,
S6K1, has been implicated in translational regulation of
mRNAs with a 5′-terminal oligopyrimidine (TOP) tract such
as those that encode ribosomal proteins, proteins involved in
translation [23]. Considering the importance of the proteins
that are subject to mTOR mediated translational control in
cell proliferation and growth, it is not surprising that cancer
cells undergo alterations that impact on mTOR activity.
Uptream Activators of mTOR
mTOR–Raptor is a component of a multisubunit complex
that is controlled by inputs from two major sources, the
phosphoinositide 3-kinase (PI3K) pathway, an important
signaling module downstream of receptor tyrosine kinases
(RTKs) [10] and the LKB1/AMP kinase (AMPK) pathway
[24] (Fig. 1). PI3K activation following growth factor stim-
ulation impacts on the Akt/PKB serine/threonine kinase,
while one of the major targets of the LKB1 serine/threonine
Figure 1 Model of the mTOR pathway; its regulation and cancer
specific alterations. mTOR lies at the interface of two major signaling
pathways, one initiated by PI3K and the other by AMPK. Mitogen
signaling to receptor tyrosine kinases activates PI3K and Akt, which
phosphorylates TSC2 leading to activation of Rheb GTPase and
mTOR activation. AMPK is a regulator of cellular energy metabolism.
In the presence of high AMP, the AMPK gamma regulatory subunit
binds AMP permitting the alpha subunit to be phosphorylated and
activated by LKB1 kinase. AMPK in turn phosphorylates TSC2,
strengthening the ability of the TSC complex to block Rheb GTPase
activity and lowering mTOR activity. The red asterisk (*) indicates
mutations leading to pathway activation in cancer. These include
constitutive activation of receptor tyrosine kinases, overexpression or
mutational activation of PI3K and Akt as well as overexpression of
Rheb and S6K1. The inverted triange (▿) indicates proteins that are
lost in cancer cells. These include PTEN, the negative regulator of
PI3K, TSC complex proteins hamartin and tuberin and the LKB1
kinase.
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kinase is AMPK, a master sensor of cellular energy supply
[25]. Control of mTOR activity is quite complex, involving
inputs from multiple regulatory proteins (Fig. 1) (Reviewed
in [4, 11, 26]. We will discuss mTOR–Raptor control at the
interphase of the PI3K and LKB1 pathways.
PI3K catalyzes production of phosphatidylinositol-3,4,5
triphosphate (PIP3) at the cell membrane, which in turn stim-
ulates the recruitment and activation of the serine/threonine
kinase Akt/protein kinase B (PKB), a major player on the
pathway. Akt is a family member of the AGC (cAMP depen-
dent, cGMP dependent and protein kinase C) protein kinases.
Binding of Akt's plekstrin homology (PH) domain to PIP3 is
necessary for phosphoinositide-dependent protein kinase 1
(PDK1) phosphorylation of Thr308 in its activation loop.
Complete Akt activation results from a second phosphoryla-
tion on Ser473 in the hydrophobic motif at its C-terminus
[27]. At least ten protein kinases have been proposed to
function as the second Akt kinase including mTOR–Rictor
as mentioned above. This second kinase is often termed
PDK2; this is currently an area under intense study. None-
theless, it is likely that multiple upstream kinases can re-
gulate Akt and other members of the AGC kinase family
(reviewed in [28]). Once activated, Akt has multiple sub-
strates, one of which is tuberin a protein directly involved in
mTOR regulation.
Tuberin, also referred to as tuberous sclerosis complex
(TSC) 2, together with hamartin, TSC1, form a heterodimeric
complex that negatively regulates mTOR signaling [29].
Tuberin is a GTPase activating protein (GAP) for the Ras-
related GTPase Rheb (Ras homologue enriched in brain).
Tuberin triggers the conversion of the active GTP-bound
Rheb to the inactive GDP-bound form [30, 31]. Following
tuberin phosphorylation and functional inactivation by Akt
[32, 33], the negative effect of TSC on Rheb function is dis-
rupted [30], and Rheb–GTP is formed. Various lines of evi-
dence suggested that Rheb acted upstream of mTOR [34],
and it is now known that Rheb binds directly to the kinase
domain of mTOR, presumably enabling a conformational
change in the mTOR–Raptor complex promoting its activa-
tion [35].
Turning to the other major pathway regulating mTOR–
Raptor, the serine/threonine kinase LKB1 was originally
identified in 1996 by Dr. J. Nezu as a novel mammalian
kinase (discussed in [24]). Interest in the kinase increased
dramatically when germline inactivating mutations in the
gene encoding LKB1 (also known as serine threonine kinase
11) were shown to be responsible for the Peutz–Jeghers syn-
drome (PJS) [36, 37]. PJS is an autosomal dominant syn-
drome characterized by benign hamartomatous polyps in the
gastrointestinal tract [38]. The LKB1 kinase has also been
implicated in sporadic cancer (discussed below).
The LKB1 kinase is part of a regulatory complex that
phosphorylates and activates AMP kinase (AMPK)-related
kinase family members (reviewed in [24]). AMPK, a master
regulator of cellular energy metabolism [25], is a hetero-
trimeric complex composed of a catalytic alpha subunit and
beta and gamma regulatory subunits. In cells with a high
AMP to ATP ratio, AMP binds the gamma subunit and in-
duces a conformational change converting the alpha subunit
into a substrate for LKB1 that phosphorylates AMPK alpha
on a threonine residue in its activation loop [39]. AMPK
activation causes numerous cellular responses, one of them
being a decrease in energy-consuming processes such as
protein synthesis, a response that connects AMPK to mTOR.
Indeed it was shown that AMPK inhibits cellular prolif-
eration under conditions of energy starvation by phos-
phorylating tuberin (TSC2) and enhancing the ability of
TSC to block mTOR signaling [40].
In summary, the two major regulators of mTOR–Raptor
activity, the PI3K/Akt and the LKB1/AMPK pathways, both
impact on TSC. Phosphorylation of tuberin by Akt blocks
the ability of the complex to interfere with Rheb activity,
thus stimulating mTOR activity. In contrast, phosphoryla-
tion of tuberin by AMPK strengthens its GAP activity to-
wards Rheb, thus resulting in a blockade of mTOR activation
(Fig. 1).
mTOR (dys)Regulation in Cancer
The mTOR pathway is abnormally activated in many tumors.
Multiple alterations, both upstream and downstream of
mTOR, leading to pathway activation have been described
(Fig. 1). In the following sections we will discuss the mech-
anisms and mutations that lead to deregulated mTOR activity
in cancer, specific data on breast cancer will be mentioned
where possible.
As discussed above two of the major mTOR substrates,
4EBP1 and S6K1 are directly involved in translational control
of mRNA coding for important cell cycle regulators and cell
growth regulators, for example, cyclin D1 and the ribosomal
proteins, respectively. Considering that cancer cells are de-
pendent upon many of these proteins for their malignant
phenotype, it is not surprising that mTOR is considered to be a
potentially important target for cancer therapy. A number of
mTOR inhibitors, as well as inhibitors of proteins on the
mTOR pathway, are in clinical development. We will end the
review with a discussion on selected pathway inhibitors.
Positive mTOR Regulators and Cancer
Amajor mTOR regulator, the PI3K/Akt pathway, is aberrantly
activated in most human tumors. Many human cancers have
alterations in RTKs that promote constitutive activation of the
PI3K/Akt pathway. Aberrant activation of the insulin like
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growth factor-1 receptor (IGF-1R) [41], the fibroblast growth
factor receptor (FGFR) family [42, 43] and members of the
epidermal growth factor receptor (EGFR)/ERBB family have
been found in many human cancers. Considering breast
cancer, approximately 20% of primary breast tumors over-
express the ErbB2 RTK due to gene amplification (reviewed
in [44]). ErbB2-overexpressing tumors show high constitu-
tive PI3K/Akt activity, mainly through coupling of ErbB2 to
ErbB3 [45], a receptor with multiple binding sites for the p85
regulatory subunit of the PI3K [46]. Overexpression and
activation of FGFR has been reported in breast cancer [42,
43] and has been linked to mTOR pathway activity [20]. The
IGF-1R has also been implicated in breast cancer, which is a
topic of another review in the issue (Sachdev and Yee).
Amplification and overexpression of the PIK3CA gene,
encoding the p110α subunit of the PI3K was found mainly
in ovarian cancers [47]. More recently, somatic point muta-
tions in the PIK3CA gene have been described in many
types of human tumors [48]. Considering breast cancer,
PIK3CA mutations have been detected in 25% of tumors
[49], making this one of the most frequently mutated genes
in this cancer. The biochemical and transforming activity of
several p110α mutants have been described [50, 51]. Ex-
pression vectors for two of the most common p110αmutations,
Glu545Lys and His1047Arg, have been introduced into human
mammary epithelial cells (HMEC); eachmutant was transform-
ing and its oncogenic potency correlated well with an enhanced
level of pathway activity [51]. The impact of enhanced PI3K
activity on mTOR was not described, however, it is likely that
tumors expressing p110α mutants maintain mTOR activity
independent from exogenous growth factor signals.
Elevated Akt1 [52] and Akt2 [53] kinase activity have
been observed in various human tumors, including breast
cancer. Activating Akt2 kinase domain mutations (2/180
tumors) [54] and AKT2 gene amplification (2/146 tumors)
have been described in a small percentage of colorectal
cancers [54] and breast cancers (3/106 tumors), as well as a
higher percentage of ovarian tumors (16/132 tumors) [55].
Thus, it appears that in breast cancer activating mutation in
the catalytic sub-unit of PI3K are more prevalent than in the
Akt kinase domain.
Rheb, the direct upstream activator of mTOR [34], has
also been found to be overexpressed at the RNA level in
many human tumors [56]. Elevated Rheb expression is likely
to impact on mTOR, since it has been shown that overex-
pression of Rheb increases the activity of the mTOR effector
protein S6K1 [34]. Moreover, the S6K1 gene is amplified in
approximately 9% of primary breast cancers [57], and ele-
vated levels of S6K1 RNA are found in almost 40% of the
tumors [58]. In summary, most of the positive regulators of
mTOR activity have been found mutated and/or overex-
pressed in human breast cancer. The most common alte-
ration found is activating mutations in the PI3K.
mTOR Regulation and Tumor Suppressors
There are three negative regulators of mTOR activity: phos-
phatase and tensin homologue deleted in chromosome 10
(PTEN), TSC and LKB1; all three have important roles in
many types of human cancer. PTEN downregulates the PI3K
pathway by dephosphorylating position D3 of PIP3 and
thereby antagonizing PI3K function. PTEN activity is lower
in many human cancers due to gene deletion, gene silencing
or mutational inactivation. Mutations in PTEN are relatively
rare in breast cancer (5%) [59, 60]. However, loss of hetero-
zygosity (LOH) [59, 61] and promoter methylation of the
PTEN gene [62], leading to low PTEN levels [63], are more
common (∼30%) in breast cancer. A recent immunohisto-
chemical analysis revealed that 26% (n = 236) of primary
breast cancers had low PTEN levels, which correlated with
lymph node metastases and a worse prognosis [64].
Thus, in addition to activating PI3K mutations in breast
cancer, PTEN, the negative regulator of the pathway is often
down-regulated. Are these mutations mutually exclusive? In
a recent analysis of ∼150 primary breast tumors, coexistence
of low PTEN levels and PI3K mutations was rare and only
detected in two cases [65]. This suggests that following muta-
tion/activation of PI3K or loss of PTEN during the genesis of
breast cancer, either of which results in an increase in PIP3
levels, there is no selective advantage for mutation of the other
gene. However, it should be mentioned that in a study of 66
endometrial cancers, PI3K mutations were more common in
tumors with PTEN mutations (46 vs. 24%) [66]. Thus, there
might be tumor type differences in the prevalence of both
alterations.
TSC is a tumor suppressor syndrome with a broad spec-
trum of clinical manifestations, including benign hamarto-
mas that occur in a wide variety of tissues such as brain, skin,
heart and kidneys [67]. As discussed above, TSC negatively
regulates mTOR activity. Hence, mTOR signaling has been
shown to be overactive in primary cells derived from hamar-
tomas in TSC patients [68] supporting the functional rela-
tionship between the hyperproliferative disease and mTOR
activation. Mutations or LOH in TSC1 and TSC2 are asso-
ciated with TSC syndrome [69]. In addition to hamartomas,
TSC patients have an increased risk of developing renal cell
carcinoma. Recently, expression of TSC proteins has also
been studied in breast cancers [70]. RNA pooled from 120
primary tumors had ∼80% decrease in hamartin specific tran-
scripts compared to the level observed in normal breast tissue.
Although there were no changes in tuberin RNA levels in the
same set, the TSC1 gene promoter was found to be heavily
methylated in some breast cancer cell lines [70], suggesting
that this tumor suppressor might be controlled by epigenetic
mechanisms. It will be important to examine the expression
levels of TSC proteins in more sets of tumors to know how
frequently these proteins are targeted in breast cancer.
56 J Mammary Gland Biol Neoplasia (2006) 11: 53–61
Germline inactivating mutations in LKB1/STK11 encod-
ing the LKB1/serine threonine kinase 11 are responsible for
PJS [36], an autosomal dominant syndrome characterized by
benign hamartomatous polyps in the gastrointestinal tract
[38]. The LKB1 kinase has also been implicated in sporadic
human cancer since it has been found that about 30% of lung
adenocarcinomas show somatic inactivating mutations in the
LKB1 gene [71]. Patients with PJS have an increased risk
for development of a variety of cancers, including breast [38,
72]; there is one report of a germline LKB1 mutation in
breast cancer [73]. Inactivating mutations in LKB1 have not
been reported in a screen of 518 kinases (the kinome) in 25
sporadic breast cancers [74]. However, an examination of
140 primary breast tumors, revealed that 30% had a geno-
mic deletion in the chromosomal region including LKB1
(19p13.2–13.3) [75]. Although follow-up studies examin-
ing the level of LKB1 protein will be necessary, these results
suggest that AMPK activation might be deregulated in breast
cancer. This alteration could have an important impact on
mTOR, for example, keeping it active under hypoxic condi-
tions, when mTOR is normally down-regulated [76].
Downstream Targets of mTOR in Cancer
A number of mTOR translational targets are known to be
activated and overexpressed in cancer and are involved in
the transformation process as well as in drug resistance. For
example, eIF-4E is overexpressed in a variety of human can-
cers, triggers tumor formation in vivo [77] and mediates Akt-
and mTOR-dependent survival and drug resistance in a
murine lymphoma model [78]. Cyclin D1, another mTOR
target [79] is overexpressed in many primary breast tumors.
These findings indicate, therefore, that targets downstream of
mTOR are also worth exploiting in cancer treatment.
These results point to the importance of aberrant mTOR
activity, and presumably alterations in translational control,
in driving the malignant phenotype. Indeed this was demon-
strated very elegantly in a study of a glioma tumor model,
where total mRNA profiles or polysomal mRNA profiles
were examined after the PI3K pathway was inhibited. The
major effect of blocking this pathway was seen at the trans-
lational and not the transcriptional level [80]. There was a
major shift in the polysome occupancy of mRNAs encod-
ing proteins involved in proliferation and growth.
Targeting the mTOR–Raptor Pathway in Cancer
The mTOR–Raptor pathway is aberrantly activated in many
human cancers. Thus, approaches to block the pathway are
being actively pursued in many laboratories and pharma-
ceutical companies. In view of the multiple regulators of
mTOR, there are a number of target proteins for which
intervention would be predicted to lower mTOR activity
and have an impact on cancer (Table 1).
Considering the broad experience gained in the 20 years
since small molecule kinase inhibitors were described [81,
82], the pathway kinases PI3K, Akt and mTOR are appealing
targets. (Inhibition of LKB1 is not desirable since this would
promote mTOR activation). Furthermore, a number of inhib-
itors blocking the cancer promoting RTKs that contribute to
PI3K pathway activation are already in the clinic [83–85].
Despite major interest in the pathway, no drugs directly tar-
geting PI3K or Akt have entered cancer trials; however, a
number are in preclinical development (reviewed in [86]).
Two well characterized inhibitors of PI3K activity, LY294002
and wortmannin, have been tested in numerous models of
cancer and shown to have antitumor activity both in vitro and
in vivo. While these compounds are not suitable for human
studies, these data provide compelling evidence that target-
ing this pathway should impact on human cancer [87].
Farnesyltransferase inhibitors (FTIs) are another interest-
ing class of therapeutics to consider as mTOR pathway in-
hibitors. Substrates for farnesyltransferase are proteins with a
C-terminal CAAX motif, including Ras family members.
FTIs were originally designed to block the action of Ras on-
coproteins, since they require a farnesyl isoprenoid mem-
brane anchor for correct cellular activity [88]. Various lines
of evidence suggest that the anti-tumor effect of FTIs is de-
pendent upon blocking the activity of other cellular proteins.
Rheb, the upstream activator of mTOR is post-translationally
modified by lipids [56] and is a strong candidate for the
anti-proliferative activity of FTIs in cancer models [34, 56].
Table 1 Inhibitors targeting the mTOR pathway in preclinical or
clinical development.
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Several FTIs are in clinical development (reviewed in [5]).
Some of these are being tested in breast cancer models [56],
and encouraging results have been obtained in a phase I
clinical trial on the FTI tipifarnib when given to advanced
breast cancer patients in combination with tamoxifen [89].
mTOR Inhibitors
The mTOR kinase is a target for rapamycin analogs, several
of which have been approved for use in transplant patients
as immunosuppressants [3]. Rapamycin and its derivatives
temsirolimus (CCI-779) [90], everolimus (RAD001) [91]
and AP-23573 [92], all of which are in clinical develop-
ment (reviewed in [5, 92]), inhibit mTOR kinase by binding
the FK506-binding protein-12 (FKBP12). The mechanism
by which this complex blocks mTOR activity is still under
investigation (discussed in [11]), and some experiments sug-
gest that FKBP12-rapamycin blocks access of mTOR sub-
strates to the complex [13]. Importantly, rapamycins inhibit
the mTOR-Raptor complex functions specifically; the mTOR–
rictor complex being insensitive to acute exposure to this class
of inhibitors [16].
Rapamycin analogues show some clinical activity, how-
ever, not on all patients. Thus, the current clinical challenge
is to determine markers that can help predict sensitivity to
mTOR inhibition in order to assist in selecting the appro-
priate patients for therapy. In this respect, animal models of
cancer might be helpful in making some predictions. In a
mouse model, the prostate was shown to be particularly sen-
sitive to PTEN levels, which dictate Akt activation and cancer
development [93]. Furthermore, an Akt driven transgenic pros-
tate tumor model was effectively treated with the mTOR in-
hibitor RAD001 [94]. A phase II clinical trial of the mTOR
inhibitor CCI-779 in prostate cancer was initiated; however,
no results have been published (discussed in [95]).
Preclinical studies suggest that breast tumor cells might
be particularly sensitive to mTOR inhibitors [21, 96]. As
mentioned above, PTEN is frequently altered in breast can-
cers, suggesting that PTEN levels might predict sensitivity to
rapamycins. Although PTEN deficiency has been correlated
with increased sensitivity to mTOR inhibitors in many tumor
models, including glioblastoma or multiple myeloma [97, 98],
a similar trend has not been observed in breast tumor cell lines
[21, 96], presumably because a number of other alterations
specifically driving breast cancer development are feeding
into the Akt/mTOR pathway. Nevertheless, in a phase II safety
trial of CCI-779 in women with advanced breast cancer three
of the four patients with PTEN deficient tumors showed
objective responses to treatment, while only 37% of the over-
all patient population (n = 28) experienced clinical benefit,
supporting the idea that patients with PTEN deficient breast
tumors might benefit from treatment with mTOR inhibitors.
ErbB2 is frequently overexpressed in breast cancers and
is correlated with poor clinical prognosis. ErbB2 overex-
pression provides a strong stimulus for PI3K/Akt pathway
activation and has been associated with increased phosphor-
ylation of mTOR effectors in primary breast cancers [99,
100], indicating that ErbB2-driven tumors might be more
dependent on mTOR signaling. Indeed, in the above-
mentioned phase II safety trial, 2 of 3 ErbB2-overexpressing
patients showed an objective response to the rapamycin
analogue, indicating that ErbB2 overexpression might be a
marker for choosing patients to treat with mTOR inhibitors.
The estrogen receptor (ER) has recently emerged as a
potential stratification marker for an increased antitumor
benefit to rapamycins in combination with endocrine ther-
apy. The ER is an important predictive and prognostic
marker in human breast cancer, being expressed in about
60% of breast cancers. It has become evident that estrogen/
ER signaling exhibits pleiotropic effects through non-
genomic interactions with growth factor signaling pathways.
In particular, long-term estrogen-deprived breast tumor cells
exhibit increased Akt/mTOR activation [101]. Moreover,
the pathway has been strongly implicated in resistance to
antiestrogen therapeutics (Reviewed in [102]). Thus, a number
of preclinical studies combining rapamycins with endocrine
therapies supported the potential for these combinations for the
therapy of endocrine-dependent breast cancers [103, 104].
The rationale to evaluate the above-mentioned markers as
potential predisposition markers is strong in breast cancer
patients. Importantly, all these alterations and resistance
mechanisms impinge on Akt signaling, eventually leading to
increased dependence onmTOR for tumor cell survival and/or
tumor progression. This rationale supports the possibility that
tumors bearing any alterations associated with increased
activated Akt levels should be particularly sensitive to mTOR
inhibition.
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